Skip to main content

Table 3 The clinicopathological criteria of HCC on top of cirrhotic and non-cirrhotic liver

From: The clinicopathological and prognostic factors of hepatocellular carcinoma: a 10-year tertiary center experience in Egypt

Parameters

Cirrhosis

n = 355

Non-cirrhosis

n = 119

p value

Age (n= 474)

 Mean age ± SD

57.21 ± 9.02

58.51 ± 10.43

0.05

 Median

58.00

60.00

Gender (n= 474)

 Male

292 (82.3%)

104 (87.4%)

0.19

 Female

63 (17.7%)

15 (12.6%)

Etiology (n= 346)

 HCV

229 (92.0%)

90 (92.8%)

1.00*

 HBV

3 (1.2%)

1 (1.0%)

 Combined HCV/HBV

2 (0.8%)

0 (0.0%)

 Non-viral

15 (6.0%)

6 (6.2%)

Previous HCV treatment (n= 217)

 IFN

23 (15.4%)

6 (8.8%)

0.16

 DAAs

86 (57.7%)

36 (52.9%)

 No treatment

40 (26.8%)

26 (38.2%)

Serum AFP (n= 258)

 < 200 ng/ml

139 (74.3%)

52 (73.2%)

0.85

 ≥ 200 ng/ml

48 (25.7%)

19 (26.8%)

Tumor focality (n= 350)

 Solitary

247 (93.6%)

73 (84.9%)

0.01

 Multiple

17 (6.4%)

13 (15.1%)

Tumor size (n= 350)

 Mean ± SD

5.51 ± 3.68

6.59 ± 3.56

< 0.001

Pathological grade (n= 443)

 I

28 (8.5%)

5 (4.5%)

0.15

 II

253 (76.4%)

83 (74.1%)

 III

50 (15.1%)

24 (21.4%)

Pathological patterns of NOS (n= 350)

 Trabecular and acinar

247 (93.6%)

73 (84.9%)

0.01

 Solid

17 (6.4%)

13 (15.1%)

Pathological stage (n= 355)

 Early stage

232 (84.4%)

61 (76.2%)

0.09

 Late stage

43 (15.6%)

19 (23.8%)

LVI (n= 358)

 Negative

157 (57.1%)

35 (42.2%)

0.02

 Positive

118 (42.9%)

48 (57.8%)

Bile duct invasion (n= 360)

 Negative

275 (100%)

82 (96.5%)

0.012

 Positive

0 (0%)

3 (3.5%)

  1. HCC hepatocellular carcinoma, HCV hepatitis C virus, HBV hepatitis B virus, IFN interferon, DAAs direct acting anti-viral, AFP alpha-fetoprotein, LVI lymphovascular invasion. Data were missed in some cases; we figured out the number beside each parameter